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(health plan name, income subsidy status). Descriptive analyses and chi-square 
tests were conducted to assess frequency distributions of the main adherence bar-
riers identified and their association with patients’ age, gender, income status, 
language and prescribers’ specialty. Results: Sample consisted of 87 hypertensive 
diabetic patients, non-adherent to ACE-Is/ARBs who received the pharmacist phone 
call. Among these patients, forgetfulness (25.29%) and doctor issue, like having diffi-
culty scheduling appointments, (16.79%) were the most commonly reported barriers. 
Other barriers identified included fear of adverse events (6.90%), cost and alterna-
tive source/insurance (5.75%), patient perception of disease and treatment (5.75%), 
dose reduction (5.75%), pharmacy related issue (3.45%), patient denial (2.30%), lost 
medication (1.15%), interruption (admission) (1.15%), transportation issues (1.15%), 
and no specified reason (2.30%). Chi-square test results were statistically insignifi-
cant (P> 0.05), thus indicating that these barriers didn’t vary across patients’ age, 
gender, language, income and prescribers’ specialty. ConClusions: Forgetfulness 
was the most commonly cited reason for non-adherence. Other barriers included 
doctor issue, fear of adverse events, cost, patient perception and dose reduction. 
Future interventions aimed at improving adherence among this high risk population 
should incorporate and address these identified barriers. KEYWORDS: Adherence, 
Intervention, ACEI/ARBs, Diabetes, Hypertension.
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objeCtives: Up to one third of older patients report cost-related medication 
non-adherence (CRMN). Diabetes is a costly chronic condition affecting 26 million 
Americans. There is an increasing recognition of the importance of CRMN in patients 
with diabetes. A behavioral framework for the factors influencing CRNM is needed 
to understand CRMN and design interventions. We aimed to develop a behavioral 
framework for CRMN among older diabetes patients. Methods: We conceptualized 
four dimensions of factors that may influence the CRMN in older diabetes patients: 
institutionalization, insurance coverage, diversity of drug utilization, and patient’s 
functional status. We used data from the 2010 Health and Retirement Study to 
assess those four dimensions. CRMN was self-reported. We conducted multivariate 
regression analysis to assess the effects of these potential risk factors. Results: 
875/4,880 (18%) of diabetes patients reported CRMN. In terms of institutionalization, 
patients residing in nursing home were 66% (p= 0.01) less likely to report CRMN; 
and having any number of hospitalizations increased the risk of CRMN (p< 0.01). 
In terms of insurance coverage, those at the pre-Medicare coverage aged 50-64 
years were 118% more likely to report CRMN compared to respondents who were 
age 65-74 (p< 0.01), and those with Medicaid were 66% less likely to report CRMN. 
In terms of drug utilization, patients using medication for asthma were 30% more 
likely to report CRMN (p< 0.01). In terms of functional status, patients with 1 or more 
limitations in activity of daily living or instrumental activities of daily living were 
much more likely to report CRMN (both p< 0.01). ConClusions: Patients’ CRMN is 
influenced by a range of factors. Interventions to reduce CRMN should target these 
factors and use these factors in identifying the target population for interventions.
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objeCtives: To evaluate the persistence rate and adherence level of new oral anti-
diabetics (OAD) users as well as their relation to patients’ demographic and clinical 
characteristics. Methods: A cohort of 160,231 patients was built from prescription 
records in the Régie de l’assurance maladie du Québec administrative database. All 
patients aged 45-85 years old who received at least one OAD prescription between 
January 2000 and October 2009 were included. New users were defined as having no 
OAD prescribed in the 2 years preceding cohort entry. The cohort entry was defined 
by the date of the first OAD prescription. Persistence rate was defined by allowing 
a 50% grace period for renewal. Drug adherence level was estimated using MPR. 
The cumulative persistence rate was estimated using a Kaplan-Meier analysis. Cox 
regression models were used to estimate the rate ratio of ceasing OAD after adjust-
ment. Logistic regression models were used to establish the relation between non-
adherence level and their determinants. Results: Patients had a mean age of 67 
years, 49% were men, 52% had a cardiovascular disease, 78% had hypertension and 
59% had dyslipidemia. Persistence decreased to 51% after 1 year but the proportion 
of patients who refilled an OAD during the year after cessation ranged from 73 to 
91%. Adherent patients (MPR ≥ 80%) accounted for 67% after 1 year. Hypertension 
(0.84-0.87), dyslipidemia (0.85-0.88) and cerebrovascular disease (0.89-0.99) were 
associated with higher persistence rates, whereas microvascular risk factors such 
as urologic procedure (1.01-1.17) and viral infectious diseases (1.09-1.27) demon-
strated lower rates. Similar results were observed for adherence. ConClusions: 
Barriers to persistence rate and adherence level occur early in the course of OAD 
therapy. Adherence is a key factor in determining the success of various therapeutic 
approaches, thus greater attention should be paid to this aspect which may result 
in improved patient outcome.
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objeCtives: To assess the impact of insulin pen needle (PN) length on persis-
tence of prescribed insulin therapy among patients recently diagnosed with type 2 
(P values <0.001) in the proportion of adherent patients (1 year  - saxagliptin: 49.1% 
vs. sitagliptin: 46.1%; 2 years – 41.5% vs. 39.3%) and the proportion of patients who 
discontinued (1 year – 43.4% vs. 46.4%; 2 years – 58.9% vs. 61.3%). Comparing saxa-
gliptin with sitagliptin, the adjusted odds ratio of being adherent during 1 year was 
1.21 (95% confidence interval: 1.16 –1.27) and during 2 years was 1.09 (1.01 –1.18). The 
adjusted hazard ratio of discontinuing saxagliptin during 1 year was 0.86 (0.84 –0.89) 
and during 2 years was 0.90 (0.86 –0.94) compared with sitagliptin. ConClusions: 
Among US adults with T2DM, saxagliptin was associated with greater adherence 
and persistence, compared with sitagliptin.  This research was funded by Bristol 
Myers Squibb and Astra Zeneca.
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objeCtives: To evaluate medication persistence with testosterone replacement 
therapy (TRT) in a US commercially-insured population. Methods: This was a 
retrospective claims database study using the MarketScan® Commercial database 
from January 2005 through December 2011. The study included men aged 18-65 
years who initiated TRT and were diagnosed with hypogonadism or hypogonado-
tropic hypogonadism (ICD-9-CM: 257.3 and 257.4). Subjects were required to have 
a minimum of 6 months continuous enrollment before and after the TRT index 
date. The main outcome was the percentage of patients who remained persistent 
with their index therapy, and estimated using the product-limit method. Results: 
Of 441,837 patients who had ≥ 1 TRT prescription claims during the study period, 
140,098 patients met all the inclusion and exclusion criteria. The mean age of the 
study population was 49.9 years (SD, 9.3 years). Most patients started with gels 
(54.1%), followed by short-acting injections (SAIs) (39%), patch (6%) and others (pel-
lets or buccal) (0.9%), respectively. Persistence with any TRT decreased substantially 
over the 36-month study period. About half of the patients were persistent with their 
TRT at 4 months while 36.9% and 24.4% of patients persisted at 6 and 12 months, 
respectively. The percentage of patients who stayed on therapy decreased to 13.6% 
(24 months) and 8.9% (36 months), respectively. For the analysis of persistence by 
formulation at 12 months, about a quarter of those receiving either gels or pellets 
remained on their initial therapy compared to 17.1% and 7.8% for SAIs and patch, 
respectively. ConClusions: This study showed that the persistence with testos-
terone replacement therapy among US patients decreased substantially over time. 
Treatment with long-acting formulations may help improving medication persis-
tence to derive long-term benefit from the therapy.
PDB93
Performance of the national quality forum DiaBetes aDherence 
measure in the mississiPPi meDicaiD PoPulation
Ramachandran S.
University of Mississippi, University, MS, USA
objeCtives: The National Quality Forum is a public organization that reviews, 
endorses, and recommends use of standardized health care quality measures, 
which are considered the gold standard in the United States. The NQF endorses 
a measure concerning medication adherence in patients with diabetes using sul-
fonylureas, thiazolidinediones or metformin. This study tests the performance 
of the diabetes adherence quality measure in the Mississippi Medicaid popula-
tion. Methods: Mississippi Medicaid administrative claims for calendar years 2008 
to 2012 were used to assess the measure in the Mississippi Medicaid fee-for-service 
population. Eligible beneficiaries were at least 18 years of age, received at least 
two prescriptions in a specific therapeutic category and did not have any claims 
for insulin in the measurement period. The patient´s measurement period was 
defined as the period from the index prescription date to the end of the calendar 
year, disenrollment, or death. Adherence was defined as the number of covered 
days divided by total number of days in the measurement period. Results: The 
study population included had a higher proportion of females (approximately 75%), 
African-Americans (around 64%) and elderly (approximately 50%). Adherence to 
Sulfonylureas, Thiazolidinediones and Metformin was approximately 38%, 41% and 
39% respectively in 2008. These numbers decreased steadily to about 26%, 35% and 
26% respectively in 2012. ConClusions: Adherence to diabetes medications has 
been decreasing in the past few years. While this might reflect a need for greater 
adherence interventions, it is possible that these numbers are being caused by 
patients who are steadily moving from the fee-for-service plan to the managed 
care plan in Mississippi Medicaid. Nevertheless, adherence to diabetes medications 
is of critical importance to measuring quality of health care delivered. This study 
provides a valuable first look at the performance of this quality measure over several 
years in a Medicaid population.
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objeCtives: To identify main adherence barriers to ACE-Is/ARBs among non-adher-
ent hypertensive diabetic patients enrolled in a Texas-based Medicare Advantage 
plan through a pharmacist telephone intervention. Methods: Subjects were mem-
bers of a Medicare prescription drug plan in Texas. Medical claims data was used 
to identify patients who were diagnosed with hypertension and diabetes with at 
least 2 fills for ACE-Is or ARBs therapy January/2013- October/2013. Patients who 
failed to refill their medication for more than one day, and had a PDC< 0.8 were 
considered non-adherent and contacted by a pharmacist to identify the adher-
ence barrier(s). Pharmacy claims data included information on demographics (age, 
gender, language), prescriber/pharmacy information, and health plan information 
